ASCO 2022: Sacituzumab Govitecan-hziy for HR-Positive/HER2-Negative Advanced Breast Cancer
Posted: 06/14/2022 | By: Chase Doyle

Question 1 of 5

In the TROPiCS-02 study, patients with HR-positive/HER2-negative advanced breast cancer randomly assigned to receive the antibody-drug conjugate sacituzumab govitecan-hziy (vs treatment of physician’s choice) had a median progression-free survival of how many months?

Choose 1